Neurofibromatosis type 2 gene mutation and its expression and tumors of digestive system

doi:10.3969/j.issn.1006-7795.2014.02.023

Abstract

CLC Number:

Zhang Ning, Huang Jian. Neurofibromatosis type 2 gene mutation and its expression and tumors of digestive system[J]. Journal of Capital Medical University, 2014, 35(2): 257-260.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2014.02.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2014/V35/I2/257

[1] Fukasawa T, Chong J M, Sakurai S, et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor[J]. Japan J Cancer Res, 2000, 91(12):1241-1249.
[2] Pylkknen L, Sarlomo-Rikala M, Wessman M, et al. Chromosome 22q alterations and expression of the NF2 gene product, merlin, in gastrointestinal stromal tumors[J]. Hum Pathol, 2003, 34(9):872-879.
[3] Ogasawara N, Sasaki M, Ishiguro H, et al. Gastric schwannoma with adjacent external progression harbored aberrant NF2 gene[J]. Dig Endosc, 2009, 21(3):192-195.
[4] Rustgi A K, Xu L, Pinney D, et al. Neurofibromatosis 2 gene in human colorectal cancer[J]. Cancer Genet Cytogenet, 1995, 84(1):24-26.
[5] Kanai Y, Tsuda H, Oda T, et al. Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas[J]. Jpn J Clin Oncol, 1995, 25(1):1-4.
[6] Yoo N J, Park S W, Lee S H. Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias[J]. Pathology, 2012, 44(1):29-32.
[7] Benhamouche S, Curto M, Saotome I, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver[J]. Genes Dev, 2010, 24(16):1718-1730.
[8] Evans D G, Sainio M, Baser M E. Neurofibromatosis type 2[J]. J Med Genet, 2000, 37(12):897-904.
[9] Morrow K A, Das S, Metge B J, et al. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation[J]. J Biol Chem. 2011, 286(46):40376-40385.
[10] Horiguchi A, Zheng R, Shen R, et al. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells[J]. Prostate, 2008, 68(9):975-984.
[11] Thurneysen C, Opitz I, Kurtz S, et al. Functional inactivation of NF2/merlin in human mesothelioma[J]. Lung cancer, 2009, 64(2):140-147.
[12] Morris Z S, McClatchey A I. Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma[J]. Proc Natl Acad Sci U S A, 2009, 106(24):9767-9772.
[13] Bretscher A, Edwards K, Fehon R G. ERM proteins and merlin: integrators at the cell cortex[J]. Nat Rev Mol Cell Biol, 2002, 3(8):586-599.
[14] Gutmann D H, Giordano M J, Fishback A S, et al. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas[J]. Neurology, 1997, 49(1):267-270.
[15] Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus[J]. Cell, 2010, 140(4):477-490.
[16] Marchler-Bauer A, Lu S, Anderson J B, et al. CDD: a Conserved Domain Database for the functional annotation of proteins[J]. Nucleic Acids Res, 2011, 39(Database issue):D225-D229.
[17] Pećina-Šlaus N. Merlin, the NF2 gene product[J]. Pathol Oncol Res, 2013, 19(3):365-373.
[18] Huang J, Chen J. VprBP targets Merlin to the Roc1-Cul4A-DDB1 E3 ligase complex for degradation[J]. Oncogene, 2008, 27(29):4056-4064.
[19] Lomas J, Bello M J, Arjona D, et al. Genetic and epigenetic alteration of the NF2 gene in sporadic meningiomas[J]. Genes Chromosomes Cancer, 2005, 42(3):314-319.
[20] Ikeda T, Hashimoto S, Fukushige S, et al. Comparative genomic hybridization and mutation analyses of sporadic schwannomas[J]. J Neurooncol, 2005, 72(3):225-230.
[21] Laniewski-Wollk M, Gos M, Koziarski A, et al. Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2[J]. J Appl Genet, 2008, 49(3):297-300.
[22] Voltaggio L, Murray R, Lasota J, et al. Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature[J]. Hum Pathol, 2012, 43(5):650-659.
[23] Zhang N, Bai H, David K K, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals[J]. Dev Cell, 2010, 19(1):27-38.
[24] Lee K P, Lee J H, Kim T S, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis[J]. Proc Natl Acad Sci U S A, 2010, 107(18):8248-8253.
[25] Xu M Z, Yao T J, Lee N P, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma[J]. Cancer, 2009, 115(19):4576-4585.
[26] Curto M, Cole B K, Lallemand D, et al. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin[J]. J Cell Biol, 2007, 177(5):893-903.
[27] Alexandrov L B, Nik-Zainal S, Wedge D C, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500(7463):415-421.

Neurofibromatosis type 2 gene mutation and its expression and tumors of digestive system

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Zhili, Guo Caixia. Clinical characteristics and risk factors of acute pulmonary embolism after operation for malignant head and neck tumors [J]. Journal of Capital Medical University, 2022, 43(5): 787-791.
[2]	Ma Mingyang, Wang Jiewei, Li Peng. Application of endocytoscopy in the valuation of colorectal lesions [J]. Journal of Capital Medical University, 2022, 43(2): 221-226.
[3]	Li Xue, Xing Jie, Zhang Qian, Li Peng, Lyu Fujing, Zhang Shutian. Diagnostic value of Japan Esophageal Society classification through narrow-band imaging technology combined with magnifying endoscopy for early esophageal cancer [J]. Journal of Capital Medical University, 2022, 43(2): 210-215.
[4]	Yao Shuyang, Li Xiaoxue, Wang Chunxiu, Zhang Yi. Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study [J]. Journal of Capital Medical University, 2022, 43(2): 289-293.
[5]	Zhao Ke, Ma Jianmin, Xiao Fei, Liu Xiangyi. Application of the mRNA of IL-6,TNF-α,GR-α and GR-β in evaluating the glucocorticoids sensitivity of patients with common orbital diseases [J]. Journal of Capital Medical University, 2021, 42(5): 747-753.
[6]	Chen Yan, Sun Ying. Progress in mRNA vaccine—The 2021 Lasker Clinical Medicine Research Award [J]. Journal of Capital Medical University, 2021, 42(5): 893-889.
[7]	Xiong Fengran, Lu Jing, Zhang Yingchao, Xie Rongrong, Zhao Ruxuan, Li Qi, Yang Jinkui. Establishment of Kcnh6 gene site-specific mutant mice modeled on a pedigree with monogenic diabetes and the phenotype analysis [J]. Journal of Capital Medical University, 2021, 42(4): 575-581.
[8]	Yu Kaiying, Wang Xiaolin, Shi Hanping. Development and progress of cancer nutrition therapy [J]. Journal of Capital Medical University, 2021, 42(3): 499-502.
[9]	Ding Mao, Yang Nan, Huang Yuyou, Shi Wenjuan, Yan Feng, Zhao Yongmei, Liu Kejian. Effects of mitochondrial reactive oxygen species inhibitor R(+)-pramipexole on JAK2-STAT3 signaling pathway and pro-inflammatory factor TNF-α in rats with cerebral ischemia/reperfusion injury [J]. Journal of Capital Medical University, 2021, 42(2): 232-238.
[10]	Li Zhu, Li Nan, Liu Zhibo, Yang Zhi. Research on glycine cell uptake mechanisms [J]. Journal of Capital Medical University, 2021, 42(1): 15-20.
[11]	Wang Xin, Zhang Junxuan, Gao Jian, Shi Hanping. Immunonutrition improves the prognosis of patients with cancer [J]. Journal of Capital Medical University, 2020, 41(6): 1019-1024.
[12]	Liu Jun, Cao Qingfei, Ye Xiongjun, Chen Weinan, Zhao Haiyue, Tong Ming, Wang Yinyin, Huang Xiaobo, Chang Zhijie. Relationship between CREPT expression and prognosis in renal cell carcinoma [J]. Journal of Capital Medical University, 2020, 41(4): 552-557.
[13]	Sun Mengxue, Wang Leiming, Teng Lianghong. Research progress on BRAF gene abnormality in glioma [J]. Journal of Capital Medical University, 2020, 41(3): 380-384.
[14]	Duan Chao, Wang Shengcai, Jin Mei, Zhang Dawei, Zhao Wen, Wang Xisi, Zhao Qian, Tai Jun, Zhang Jie, He Lejian, Zhang Jianguo, Ni Xin, Ma Xiaoli. Clinical features and outcome regarding head and neck non-rhabdomyosarcoma soft tissue sarcoma in children [J]. Journal of Capital Medical University, 2019, 40(6): 921-926.
[15]	Yang Yanlin, Chen Guangqiang, He Xuan, Shi Zhonghua, Xu Ming, Zhou Jianxin. Application of the critical-care pain observation tool for pain assessment in intracranial tumor patients after craniotomy [J]. Journal of Capital Medical University, 2019, 40(5): 758-763.